Expression of HDAC4 in human lung adenocarcinoma and its relationship with chemotherapy resistance
10.16571/j.cnki.1008-8199.2017.05.013
- VernacularTitle:组蛋白去乙酰化酶4在人肺腺癌组织中的表达水平及其与化疗耐药的关系
- Author:
Dongqin CHEN
;
Fei CAO
;
Min TAO
;
Hong ZHU
;
Longbang CHEN
- Keywords:
Histone deacetyltransferase 4;
Lung adenocarcinoma;
Chemoresistance
- From:
Journal of Medical Postgraduates
2017;30(5):512-514
- CountryChina
- Language:Chinese
-
Abstract:
Objective There have been few research on the relationship between expression of HDAC4 and chemotherapy resistance in human lung adenocarcinoma.The present study aims to investigate the expression and clinical significance of HDAC4 in human lung adenocarcinoma tissues.Methods We selected 72 tissues in lung adenocarcinoma patients with docetaxel-resistant from January 2006 to December 2007 in Department of Oncology and Thoracic Surgery, Nanjing General Hospital of Nanjing Military Region, then evaluated the recent efficacy according to the RECIST criteria and divided the tissues into sensitive(n=32, included complete remission and partial remission) and insensitive(n=40, included stability and progress) groups.The expression of HDAC4 in tissues≥the HDAC4 optimal relative expression cut-off value(78.7) was high level HDAC4 group(n=35), otherwise it was low level HDAC4 group(n=37).QRT-PCR analysis was performed to detect the HDAC4 expression levels in sensitive group and insensitive group.Analyzed the progression free survival in high level HDAC4 group and low level HDAC4 group.Results The expression of HDAC4 was significantly higher in the insensitive group compared with the sensitive group [(1.42±0.30) vs (0.60±0.15), P<0.01].The median progression free survival was significantly shortened in the high level HDAC4 group compared with the low level HDAC4 group (10.2 months vs 5.8 months, P<0.05).ConclusionThe expression of HDAC4 increased in docetaxel-resistant lung adenocarcinoma patients, and it is expected to be a predictive indicator of the resistance of docetaxel.
